Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395285 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
A Phase 1 study of ROSAH, sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT06395285: Recruiting Phase 1 study of ROSAH, sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm).
NCT06395285 is a Phase 1 study of ROSAH that is actively recruiting participants, run by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm). The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06395285, a Phase 1 study of ROSAH, is actively recruiting participants, sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Conditions Studied
Interventions
- DRUG DF-003
Study Locations (4)
Maryland
- National Institutes of Health Clinical Center - Bethesda
North Carolina
- Duke Eye Center - Duke University Hospital - Durham
Utah
- John A. Moran Eye Center - University of Utah Health - Salt Lake City
New South Wales
- Save Sight Institute - University of Sydney Eye Hospital - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT06395285 shows while recruiting
NCT06395285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with ROSAH appearing as the primary indexed condition, and to 1 intervention - of which DF-003 is the first listed.
NCT06395285 reports a single indexed study location in Maryland, North Carolina, Utah.
Frequently Asked Questions
What is clinical trial NCT06395285 about?
NCT06395285 is a clinical study titled "Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients". The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
What is the current status of trial NCT06395285?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-27. Estimated completion is 2026-05.
What conditions does trial NCT06395285 study?
This clinical trial studies the following conditions: ROSAH.
What interventions are being tested in trial NCT06395285?
The interventions under investigation include: DF-003 (DRUG).
Who is sponsoring clinical trial NCT06395285?
This trial is sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06395285 being conducted?
This trial has 4 study locations across Maryland, North Carolina, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ROSAH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06395285's enrollment target sits among peer trials
12 1853rd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI